Baseline characteristics of participants in the intention-to-treat population
| Overall | Conventional | Orthèse Diabète | Missing data (n) | |
| Number | 112 | 58 | 54 | |
| Female | 24 (21) | 9 (16) | 15 (28) | 0 |
| Age (years) | 62±10 | 61±10 | 63±11 | 0 |
| BMI (kg/m²) | 31±6 | 30±6 | 31±5 | 4 |
| Heart rate (bpm) | 77±11 | 76±12 | 78±10 | 12 |
| SBP (mm Hg) | 136±18 | 135±18 | 137±19 | 7 |
| DBP (mm Hg) | 75±11 | 75±10 | 75±12 | 7 |
| Diagnosed diabetes duration (years) | 19±9 | 20±10 | 19±8 | 0 |
| Type of diabetes | 0 | |||
| 1 | 12 (11) | 8 (14) | 4 (7) | |
| 2 | 100 (89) | 50 (86) | 50 (93) | |
| HbA1c | 19 | |||
| (%) | 8.1±1.9 | 8.2±2.1 | 8.0±1.6 | |
| (mmol/mol) | 65±20 | 66±17 | 64±13 | |
| eGFR (mL/min/1.73 m2) | 71±31 | 70±31 | 72±31 | 0 |
| History of diabetic nephropathy | 10 | |||
| Microalbuminuria | 34 (30) | 20 (34) | 14 (26) | |
| Macroalbuminuria | 22 (20) | 12 (21) | 10 (19) | |
| End-stage renal disease | 11 (10) | 6 (10) | 5 (9) | |
| History of diabetic retinopathy | 6 | |||
| Non-proliferative | 29 (26) | 15 (26) | 14 (26) | |
| Proliferative | 38 (34) | 22 (38) | 16 (30) | |
| Current smokers | 20 (18) | 13 (23) | 7 (13) | 3 |
| History of coronary heart disease | 25 (21) | 17 (29) | 8 (15) | 3 |
| History of stroke | 2 (2) | 1 (2%) | 1 (2%) | 4 |
| Current treatments | ||||
| Insulin therapy | 54 (48) | 27 (47) | 27 (50) | 0 |
| Diuretics | 17 (15) | 10 (17) | 7 (13) | 0 |
| Beta-blocking agents | 17 (15) | 9 (16) | 8 (15) | 0 |
| Calcium channel blockers | 21 (19) | 11 (19) | 10 (19) | 0 |
| Renin-angiotensin system blockers | 30 (27) | 11 (19) | 19 (35) | 0 |
| Oral antibacterial | 23 (21) | 15 (26) | 8 (15) | 0 |
| Lipid-modifying agents | 38 (34) | 18 (31) | 20 (37) | 0 |
| Antithrombotic agents | 35 (31) | 16 (28) | 19 (35) | 0 |
Data expressed as number (percentage) of participants and mean±SD.
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; SBP, systolic blood pressure.